drugset / Trial / NCT00998322

A Study of REOLYSIN® in Combination With Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma

NCT00998322

Phase 2 Completed 34 enrolled Oncolytics Biotech University of Texas · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this Phase 2 study is to investigate whether intravenous administration of REOLYSIN therapeutic reovirus in combination with gemcitabine is effective and safe in the treatment of patients with advanced pancreatic cancer.

Timeline

Start
2009-10
Primary completion
2013-12
Completion
2015-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Gemcitabine Small molecule 800 mg/m2 Intravenous
Subject Pelareorep Other / unclassified 1e+10 unknown Intravenous